
AIM
AIM ImmunoTech Inc
$0.44
0.20%Name
AIM ImmunoTech Inc
Website
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
Categories
Health TechnologyBiotechnologyManufacturingBiological Product (except Diagnostic) Manufacturing
CEO
Thomas Equels
Employees
23
Description
aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as
Market Cap
$21.51M
52 Week High
$0.84
PE Ratio
-1.10
52 Week Low
$0.29
EPS
-$0.40
Shares Outstanding
48.67M
Dividend Yield
-
Dividend Per Share
-
Name
AIM ImmunoTech Inc
Website
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
Categories
Health TechnologyBiotechnologyManufacturingBiological Product (except Diagnostic) Manufacturing
CEO
Thomas Equels
Employees
23
Description
aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as